PH12016500461A1 - Polyethylene glycol-containing composition - Google Patents

Polyethylene glycol-containing composition

Info

Publication number
PH12016500461A1
PH12016500461A1 PH12016500461A PH12016500461A PH12016500461A1 PH 12016500461 A1 PH12016500461 A1 PH 12016500461A1 PH 12016500461 A PH12016500461 A PH 12016500461A PH 12016500461 A PH12016500461 A PH 12016500461A PH 12016500461 A1 PH12016500461 A1 PH 12016500461A1
Authority
PH
Philippines
Prior art keywords
polyethylene glycol
containing composition
salt
formula
pharmaceutical composition
Prior art date
Application number
PH12016500461A
Other languages
English (en)
Inventor
Murai Kenji
Yamada Kazuhito
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PH12016500461A1 publication Critical patent/PH12016500461A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
PH12016500461A 2013-09-20 2016-03-09 Polyethylene glycol-containing composition PH12016500461A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013195329 2013-09-20
PCT/JP2014/074698 WO2015041294A1 (ja) 2013-09-20 2014-09-18 ポリエチレングリコール含有組成物

Publications (1)

Publication Number Publication Date
PH12016500461A1 true PH12016500461A1 (en) 2016-05-16

Family

ID=52688941

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016500461A PH12016500461A1 (en) 2013-09-20 2016-03-09 Polyethylene glycol-containing composition

Country Status (17)

Country Link
US (1) US20160228420A1 (enExample)
EP (1) EP3047850A4 (enExample)
JP (2) JP5856264B2 (enExample)
KR (1) KR20160060656A (enExample)
CN (1) CN105555271A (enExample)
AU (1) AU2014322111A1 (enExample)
BR (1) BR112016006153A2 (enExample)
CA (1) CA2924628A1 (enExample)
EA (1) EA201690621A1 (enExample)
HK (2) HK1220632A1 (enExample)
IL (1) IL244648A0 (enExample)
MX (1) MX2016003566A (enExample)
MY (1) MY163236A (enExample)
PH (1) PH12016500461A1 (enExample)
SG (1) SG11201602020QA (enExample)
TW (1) TW201518291A (enExample)
WO (1) WO2015041294A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI677346B (zh) * 2015-03-17 2019-11-21 日商參天製藥股份有限公司 含有多肽之醫藥組成物
HK1246641A1 (zh) 2015-03-18 2018-09-14 参天制药株式会社 缓释性医药组合物
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
JP6872322B2 (ja) * 2015-07-01 2021-05-19 参天製薬株式会社 クエン酸エステルを含有するデポ剤
CN106902117A (zh) * 2015-12-23 2017-06-30 瑞阳(苏州)生物科技有限公司 一种预防或治疗脉络膜新生血管形成的药物
JP7018939B2 (ja) * 2016-09-26 2022-02-14 ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA833692B (en) * 1982-05-28 1985-02-27 Beecham Group Plc Pharmaceutical formulations
JPS59101478A (ja) * 1982-11-29 1984-06-12 Sunstar Inc リグスチライドを安定に配合した水系組成物
JPH09110698A (ja) * 1995-10-19 1997-04-28 Taiho Yakuhin Kogyo Kk 経口用医薬組成物の製造法
US7544703B2 (en) 2004-02-17 2009-06-09 Santen Pharmaceutical Co., Ltd. Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
ES2368153T3 (es) * 2004-02-17 2011-11-14 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo.
US20060153920A1 (en) * 2004-09-24 2006-07-13 Ketan Amin Lyophilized pharmaceutical compositions
CA2597590A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2693888A1 (en) 2007-07-20 2009-01-29 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
BRPI0819849B8 (pt) * 2007-11-26 2021-05-25 Merial Ltd sistemas de solvente para formulações pour on para combater parasitas
CN105362221A (zh) 2009-03-03 2016-03-02 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
AU2010271746B2 (en) * 2009-07-17 2014-07-03 Santen Pharmaceutical Co., Ltd. 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof
WO2011094565A1 (en) * 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Also Published As

Publication number Publication date
HK1220632A1 (zh) 2017-05-12
CN105555271A (zh) 2016-05-04
WO2015041294A1 (ja) 2015-03-26
JP5856264B2 (ja) 2016-02-09
US20160228420A1 (en) 2016-08-11
IL244648A0 (en) 2016-04-21
JP2016094442A (ja) 2016-05-26
MX2016003566A (es) 2016-06-02
SG11201602020QA (en) 2016-04-28
KR20160060656A (ko) 2016-05-30
TW201518291A (zh) 2015-05-16
MY163236A (en) 2017-08-30
EP3047850A4 (en) 2017-05-10
CA2924628A1 (en) 2015-03-26
JP2015083565A (ja) 2015-04-30
AU2014322111A1 (en) 2016-04-07
HK1221407A1 (en) 2017-06-02
EA201690621A1 (ru) 2016-07-29
BR112016006153A2 (pt) 2017-08-01
EP3047850A1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
JOP20180102B1 (ar) مركب صيدلاني
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
PH12016500806A1 (en) Urea derivative or pharmacologically acceptable salt thereof
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
IN2015DN00598A (enExample)
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12015500900B1 (en) A stabilized pemetrexed formulation
MX2015010106A (es) Moduladores de la proteina activadora de 5-lipoxigenasa.
PH12015502665A1 (en) Improvements in or relating to organic compounds
EA033168B1 (ru) СТИМУЛЯТОРЫ sGC
MX2015008829A (es) Momelotinib deuterado.
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
MX2018001517A (es) Derivados sustituidos de guanidina.
MX2016003566A (es) Composicion que contiene polietilen glicol.
NZ627473A (en) Aryloxyacetamide compound and pesticide
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
PH12015501146A1 (en) Hydantoin derivative
WO2014172363A3 (en) Combretastatin analogs
NZ717192A (en) Anti-inflammatory tripeptides
EA201690908A1 (ru) Пиразолопиримидиновые соединения